Resource Summary Report

Generated by dkNET on Aug 17, 2026

Brilliant Violet 510(TM) anti-human CD20

RRID:AB_2561941
Type: Antibody

Proper Citation

BioLegend Cat# 302340, RRID:AB_2561941

Antibody Information

URL: http://antibodyregistry.org/AB_2561941

Proper Citation: BioLegend Cat# 302340, RRID:AB_2561941

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD20

Description: This monoclonal targets CD20

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone 2H7

Antibody ID: AB_2561941

Vendor: BioLegend

Catalog Number: 302340

Alternative Catalog Numbers: 302339

Record Creation Time: 20250820T034148+0000

Record Last Update: 20250820T165649+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD20.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD20.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. Cell stem cell, 33(6), 982.

da Silva Antunes R, et al. (2025) Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters. Cell reports, 44(7), 115907.

Fantin RF, et al. (2025) Human monoclonal antibodies targeting A35 protect from death caused by mpox. Cell.

Agarwal R, et al. (2025) Chikungunya virus-specific CD4+ T cells are associated with chronic chikungunya viral arthritic disease in humans. Cell reports. Medicine, 6(5), 102134.

Wang X, et al. (2025) Identification of a broad-inhibition influenza neuraminidase antibody from pre-existing memory B cells. Cell host & microbe, 33(1), 151.

Salgia NJ, et al. (2025) Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma. Cancer cell.

Tarke A, et al. (2024) SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire. Cell reports. Medicine, 5(6), 101583.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.

Williams GP, et al. (2023) Unaltered T cell responses to common antigens in individuals with Parkinson's disease. Journal of the neurological sciences, 444, 120510.

Sureshchandra S, et al. (2023) Multimodal profiling of term human decidua demonstrates immune adaptations with pregravid obesity. Cell reports, 42(7), 112769.

Cobos Jiménez V, et al. (2023) AP-1/c-Fos supports SIV and HIV-1 latency in CD4 T cells infected in vivo. iScience, 26(10), 108015.

Zhang Z, et al. (2022) Humoral and cellular immune memory to four COVID-19 vaccines. Cell, 185(14), 2434.

Rhoades NS, et al. (2022) Functional, transcriptional, and microbial shifts associated with healthy pulmonary aging in rhesus macaques. Cell reports, 39(3), 110725.

Tarke A, et al. (2022) SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell, 185(5), 847.

Sun P, et al. (2022) Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern. iScience, 25(10), 105202.

Giron LB, et al. (2020) Interferon-? alters host glycosylation machinery during treated HIV infection. EBioMedicine, 59, 102945.

Weisberg SP, et al. (2019) Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway. Cell reports, 29(12), 3916.